Galanin-like immunoreactivity in hippocampal afferents in the rat, with special reference to cholinergic and noradrenergic inputs

N-terminal galanin-(1-16) fragment is an agonist at the hippocampal galanin receptor

The galanin N-terminal fragment [galanin-(1-16)] has been prepared by solid-phase synthesis and by enzymic cleavage of galanin by endoproteinase Asp-N. This peptide fragment displaced 125I-labeled galanin in receptor autoradiography experiments on rat forebrain and spinal cord and in equilibrium binding experiments from high-affinity binding sites in the ventral hippocampus with an IC50 of approximately 3 nM. In tissue slices of the same brain area, galanin-(1-16), similarly to galanin, inhibited the muscarinic agonist-stimulated breakdown of inositol phospholipids. Upon intracerebroventricular administration, galanin-(1-16) (10 micrograms/15 microliters) also inhibited the scopolamine (0.3 mg/kg, s.c.)-evoked release of acetylcholine, as studied in vivo by microdialysis. Substitution of [L-Trp2] for [D-Trp2] resulted in a 500-fold loss in affinity as compared with galanin-(1-16). It is concluded that, in the ventral hippocampus, the N-terminal galanin fragment [galanin-(1-16)] is recognized by the galanin receptors controlling acetylcholine release and muscarinic agonist-stimulated inositol phospholipid breakdown as a high-affinity agonist and that amino acid residue [Trp2] plays an important role in the receptor-ligand interactions.

Co-existence of galanin and acetylcholine: is galanin involved in memory processes and dementia?

Galanin-like immunoreactivity co-exists with choline acetyltransferase-like immunoreactivity in neurons of the septal-hippocampal and nucleus basalis of Meynert-neocortical pathways. These structures mediate some forms of cognition, and characteristically degenerate in Alzheimer's disease. Biochemical, neurophysiological and behavioral studies indicate that galanin acts as an inhibitory modulator of cholinergic function. In this article, we consider the possibility of a role for galanin in memory processes and dementia.

Galanin blocks the slow cholinergic EPSP in CA1 pyramidal neurons from ventral hippocampus

Using intracellular recordings from slice preparations, we studied the effects of the peptide galanin on the properties of CA1 pyramidal neurons from rat ventral hippocampus. Galanin, applied in the superfusing medium, had a weak and inconsistent effect on the membrane potential or on the afterhyperpolarization which follows a train of spikes. Galanin, which is localized in some cholinergic neurons of the septo-hippocampal pathway, did not affect the action of acetylcholine or carbachol on CA1 pyramidal neurons. However, it did have a presynaptic inhibitory effect on the cholinergic terminals, blocking the slow cholinergic excitatory post-synaptic potential (EPSP) induced by the release of endogenous acetylcholine on the pyramidal neurons. This effect was reversible and mimicked by atropine. These results suggest that the peptide galanin, colocalized with acetylcholine in some septo-hippocampal neurons might play a role in the control of acetylcholine release.

Cranial motor neurons contain either galanin- or calcitonin gene-related peptidelike immunoreactivity

The demonstration of coexistence of a peptide or peptides in neurons that produce a small molecule neurotransmitter has become increasingly frequent. The calcitonin gene-related peptide (CGRP) is known to be colocalized in the cholinergic neurons of both cranial and spinal motor nuclei. The present study demonstrates that all somatic motor cranial nerve nuclei contain CGRP- and galaninlike immunoreactivity. The perikaryal content of both peptides is increased by colchicine pretreatment and by transecting axons arising from the perikarya, and both peptides are found in nerve fibers innervating striated musculature. CGRP- and galaninlike immunoreactivity appear to be present in different populations of neurons. In contrast to CGRP, galaninlike immunoreactivity was not detected in spinal motor neurons. These observations suggest that galanin and CGRP participate in the process of synaptic transmission at the neuromuscular junction of cranial motor neurons.

Peptidergic neurons in the basal forebrain magnocellular complex of the rhesus monkey

The basal forebrain magnocellular complex of primates is defined by the presence of large, hyperchromic, usually cholinergic neurons in the nucleus basalis of Meynert and nucleus of the diagonal band of Broca. Because there is growing evidence for noncholinergic neuronal elements in the basal forebrain complex, five neuropeptides and the enzyme choline acetyltransferase were studied immunocytochemically in this region of rhesus monkeys. Galaninlike immunoreactivity coexists with choline-acetyl-transferase-like immunoreactivity in most large neurons and in some smaller neurons of the primate nucleus basalis and nucleus of the diagnonal band. Four other peptides show immunoreactivity in more limited regions of the basal forebrain complex, usually in separate smaller, noncholinergic neurons. Numerous small, somatostatinlike-immunoreactive neurons occupy primarily anterior and intermediate segments of the nucleus basalis, especially laterally and ventrally. Somewhat fewer, small neuropeptide Y-like-immunoreactive somata are found in the same regions. Neurons that show neurotensinlike immunoreactivity are slightly larger than cells that contain immunoreactivity for somatostatin or neuropeptide Y, but these neurons also occur mainly in anterior and intermediate parts of the nucleus basalis. Overall, the usually small, leucine-enkephalin-like-immunoreactive neurons are infrequent in the basal forebrain complex and are most abundant in the rostral intermediate nucleus basalis. Thus, neurons that appear to contain somatostatin, neuropeptide Y, neurotensin, or enkephalin mingle with cholinergic/galaninergic neurons only in some subdivisions of the nucleus basalis/nucleus of the diagonal band, and their distributions suggest that some of these small neurons could be associated with structures that overlap with cholinergic neurons of the labyrinthine basal forebrain magnocellular complex. We also have found light microscopic evidence for innervation of basal forebrain cholinergic neurons by boutons that contain galanin-, somatostatin-, neuropeptide Y-, neurotensin-, or enkephalinlike immunoreactivity. The origins and functions of these putative synapses remain to be determined.

Galanin-like immunoreactivity within Ch2 neurons in the vertical limb of the diagonal band of Broca in aging and Alzheimer's disease

The neuropeptide galanin is known to inhibit the evoked release of acetylcholine in ventral hippocampus of the rat. Co-localization of this peptide with choline acetyltransferase in neurons of the cholinergic septal nuclei has been demonstrated in the rat and non-human primate. The severe deficiency of the cholinergic hippocampal projection system arising mainly from the vertical limb nucleus of the diagonal band of Broca, also referred to as Ch2 region, is a constant finding in Alzheimer's disease, a disorder which is neuropathologically characterized by the appearance of senile plaques, neurofibrillary tangles and congophilic angiopathy in neo- and archicortical structures. In the present study for the first time galanin immunoreactivity in the human Ch2 region is morphologically investigated and related to the severity of hippocampal plaques and neurofibrillary tangles in Alzheimer's disease. An inverse relationship between decreasing galanin immunoreactivity in the Ch2 region and amounts of senile plaques and neurofibrillary tangles in the hippocampus is indicated. Considering the cholinergic deficiency in Alzheimer's disease as a secondary phenomenon to primary cortical and hippocampal lesions, and realizing the inhibitory effect of galanin upon acetylcholine release in hippocampus, this preliminary study suggests that a decreased galanin immunoreactivity in Ch2 in Alzheimer's disease, reflects a possible negative feedback mechanism to a degenerating cholinergic projection system.

Brain neuropeptides: actions on central cardiovascular control mechanisms

The many peptides we have not considered (e.g. gastrin, motilin, FMRFamide, carnosine, litorin, dermorphin, casomorphin, eledoisin, prolactin, growth hormone, neuromedin U, proctolin, etc.) were omitted due to lack of information as far as any putative central cardiovascular effects are concerned. However, even for some of these peptide pariahs intriguing snippets of information are available now (e.g. ref. 85), although as we write, the list of possible candidates for investigation grows longer. On an optimistic note, it is becoming clear that many brain neuropeptides may have important effects on cardiovascular regulation. It seems feasible that 'chemically coded' pathways in the brain might be the neuroanatomical correlate of a 'viscerotopic' organization of cardiovascular control mechanisms, whereby the activity of the heart and flows through vascular beds are individually controlled, but in an integrated fashion, utilizing particular combinations of neurotransmitters and neuropeptides within the brain. Such possibilities can only be investigated, properly, by measurement of changes in cardiac output and regional haemodynamics in response to appropriate interventions, in conscious, unrestrained animals.

Galanin antagonizes acetylcholine on a memory task in basal forebrain-lesioned rats

Galanin coexists with acetylcholine in medial septal neurons projecting to the ventral hippocampus, a projection thought to modulate memory functions. Neurochemical lesions of the nucleus basalis-medial septal area in rats impaired choice accuracy on a delayed alternation t-maze task. Acetylcholine (7.5 or 10 micrograms intraventricularly or 1 micrograms micro-injected into the ventral hippocampus) significantly improved performance in the lesioned rats. Atropine (5 mg/kg intraperitoneally or 10 micrograms intraventricularly), but not mecamylamine (3 mg/kg intraperitoneally or 20 micrograms intraventricularly), blocked this action of acetylcholine, suggesting involvement of a muscarinic receptor. Galanin (100-500 ng intraventricularly or 200 ng into the ventral hippocampus) attenuated the ability of acetylcholine to reverse the deficit in working memory in the lesioned rats. The antagonistic interaction between galanin and acetylcholine suggests that endogenous galanin may inhibit cholinergic function in memory processes, particularly in pathologies such as Alzheimer disease that involve degeneration of basal forebrain neurons.

Galanin-like immunoreactivity is unchanged in Alzheimer's disease and Parkinson's disease dementia cerebral cortex

Galanin is a recently isolated neuropeptide that is of particular interest in dementing disorders because of its known colocalization with choline acetyltransferase in magnocellular neurons of the basal nucleus of Meynert. These neurons degenerate in Alzheimer's disease, and there is a corresponding deficiency of cortical choline acetyltransferase activity. In the present study, galanin-like immunoreactivity was measured in the postmortem cerebral cortex and hippocampus of 10 controls and 14 patients who had had Alzheimer's disease. Significant reductions of choline acetyltransferase activity (50-60%) were found in all regions examined; however, there was no significant effect on concentrations of galanin-like immunoreactivity. Similar measurements were made in postmortem tissues of 12 control and 13 demented Parkinsonian patients who had had Alzheimer-type cortical pathology. Choline acetyltransferase activity was again significantly decreased in all regions examined but there were no significant reductions in galanin-like immunoreactivity. Experimental lesions of the fornix in rats produced parallel significantly correlated reductions of both choline acetyltransferase activity and galanin-like immunoreactivity in the hippocampus. Galanin-like immunoreactivity in the human hypothalamus consisted of two molecular-weight species on gel-permeation chromatography, and two forms were resolved by reverse-phase HPLC. The paradoxical preservation of galanin-like immunoreactivity, despite depletion of the activity of choline acetyltransferase, with which it is colocalized, is as yet unexplained. Recent studies have shown that galanin inhibits both acetylcholine release in the hippocampus and memory acquisition; therefore, preserved galanin may exacerbate the cholinergic and cognitive deficits that accompany dementia.

The effect of cholinergic blockade on the growth hormone response to galanin in humans

The effect of cholinergic blockade with pirenzepine or atropine on growth hormone (GH) release after galanin administration was investigated in five normal male subjects. The mean peak GH response to an infusion of galanin (40 pmol/kg/min for 40 minutes) was significantly reduced from 17.2 mU/L to 2.9 mU/L (P less than .001) with prior administration of pirenzepine (30 mg IV). When galanin was infused at a higher dose (80 pmol/kg/min), this suppression of release by pirenzepine was partially overcome, with GH rising to a mean peak response of 8.0 mU/L (P less than .05). Repeated administration of atropine (two bolus doses of 0.6 mg IV) also failed to abolish the GH response to this higher dose of galanin in two subjects. It has been proposed that cholinergic pathways control GH release via somatostatin, and this study suggests that galanin may also act by modulating hypothalamic somatostatinergic tone either directly or by facilitating cholinergic transmission.

Distribution of galanin-like immunoreactivity in baboon brain

Galanin-like immunoreactivity (GLI) was measured in baboon brains using a recently developed radioimmunoassay. Concentrations were measured in 10 cortical regions, hippocampus and 20 subcortical regions. The highest concentrations were in the median eminence, followed by hypothalamus, locus ceruleus, periaqueductal grey, bed nucleus of the stria terminalis, septum, amygdala and substantia innominata. Substantial amounts were also measurable in the inferior olive, basal ganglia and thalamus with very low levels in cerebellum. In cerebral cortex, concentrations were lowest in occipital cortex and highest in dorsolateral frontal cortex. Hippocampal concentrations were higher than those in cerebral cortex. Concentrations of GLI in cerebral cortex were significantly correlated with choline acetyltransferase activity and substance P immunoreactivity but not with concentrations of somatostatin or neuropeptide Y. Approximately half the GLI coeluted with porcine standards while half corresponded to a lower molecular weight species on gel permeation chromatography. With reverse phase high performance liquid chromatography (HPLC) the majority of the immunoreactivity eluted just in front of the porcine standard with a smaller amount coeluting with the porcine standard. These results show a widespread distribution of GLI in primate brain and are in accord with previous immunocytochemical studies.

Effects of PVN galanin on macronutrient selection

The neuropeptide galanin (GAL), after injection into the hypothalamic paraventricular nucleus (PVN), elicited a potent feeding response. In satiated rats maintained on pure macronutrient diets (protein, carbohydrate and fat), PVN GAL injection was found to cause a preferential increase in the consumption of the fat diet, with a significantly smaller increase in carbohydrate intake and no change in protein ingestion. When the fat diet was removed, GAL's stimulatory effect on carbohydrate ingestion was reliably and selectively enhanced. These effects of GAL stand in contrast to those of neuropeptide Y (NPY), which is co-localized with NE in the PVN and which induced in these animals a strong and selective enhancement of carbohydrate intake after PVN injection. Similarly, PVN NE, known to act via alpha 2-noradrenergic receptors, induced feeding specifically of carbohydrate and, to a small extent, fat. These differential results demonstrate the specificity of the effects of the peptides (GAL and NPY) and NE on macronutrient selection, all of which can be repeatedly observed in the same group of animals and which appear to be unrelated to the rats' natural 24 hr baseline preferences. However, we did observe a strong positive correlation between NE- and GAL-induced carbohydrate intake. In light of this relationship and additional pharmacological evidence linking GAL- and NE-induced feeding, it is proposed that the effects of GAL on macronutrient selection may be mediated, at least in part, by the alpha 2-noradrenergic feeding system within the PVN.

Galanin inhibits acetylcholine release in the ventral hippocampus of the rat: histochemical, autoradiographic, in vivo, and in vitro studies

A high density of galanin binding sites was found by using 125I-labeled galanin, iodinated by chloramine-T, followed by autoradiography in the ventral, but not in the dorsal, hippocampus of the rat. Lesions of the fimbria and of the septum caused disappearance of a major population of these binding sites, suggesting that a large proportion of them is localized on cholinergic nerve terminals of septal afferents. As a functional correlate to these putative galanin receptor sites, it was shown, both in vivo and in vitro, that galanin, in a concentration-dependent manner, inhibited the evoked release of acetylcholine in the ventral, but not in the dorsal, hippocampus. Intracerebroventricularly applied galanin (10 micrograms/15 microliters) fully inhibited the scopolamine (0.5 mg/kg, s.c.)-stimulated release of acetylcholine in the ventral, but not in the dorsal, hippocampus, as measured by microdialysis technique. In vitro, galanin inhibited the 25 mM K+-evoked release of [3H]acetylcholine from slices of the ventral hippocampus, with an IC50 value of approximately 50 nM. These results are discussed with respect to the colocalization of galanin- and choline acetyltransferase-like immunoreactivity in septal somata projecting to the hippocampus.